Triple-Threat attack on tough blood cancers begins human testing
NCT ID NCT05010122
Summary
This study is testing a new combination of three oral drugs (ASTX727, venetoclax, and gilteritinib) for adults with specific types of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that have a genetic change called an FLT3 mutation. The first part aims to find the safest dose, and the second part will see how well the combination works to control the disease. The goal is to see if this approach helps patients who are newly diagnosed, or whose cancer has returned or not responded to prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.